Showing results (71-80 of 97) with videos related to
Sort By:
Pageof 10
German Medical Science : GMS E-Journal|July 1, 2021
Advisory opinion of the AWMF Ad hoc Commission In-vitro Diagnostic Medical Devices regarding in-vitro diagnostic medical devices manufactured and used only within health institutions established in the Union according to Regulation (EU) 2017/746 (IVDR)Petra Hoffmüller, Monika Brüggemann, Thomas Eggermann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studiesTorsten Haferlach, Claudia Schoch, Helmut Löffler, et al.Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.Haematologica|April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyMarie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database mergeJulie Schanz, Heinz Tüchler, Francesc Solé, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study groupJan Krönke, Richard F Schlenk, Kai-Ole Jensen, et al.Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.Pageof 10